Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6013
Abstract: OBJECTIVE Checkpoint inhibitors (CPIs) are in widespread clinical use. Little is known about which patients are at risk for developing toxicity. It is essential being able to identify patients with higher risk of experiencing immune-related… read more here.
Keywords: frailty score; simplified frailty; iraes; score ... See more keywords
Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-021-02880-0
Abstract: The aim of this retrospective study was to demonstrate that irAEs, specifically gastrointestinal and pulmonary, examined through International Classification of Disease (ICD) data leads to underrepresentation of true irAEs and overrepresentation of false irAEs, thereby… read more here.
Keywords: claims data; icd claims; icd; review ... See more keywords
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Journal of Gastroenterology"
DOI: 10.1007/s12328-020-01317-y
Abstract: Systemic administration of anti-programmed cell death 1 (PD-1) antibody (Ab) has achieved remarkable success in metastatic cancers. The blockade of PD-1-mediated signaling pathways sometimes cause immune-related adverse events (irAEs) due to restored anti-cancer as well… read more here.
Keywords: accumulation; immune related; case; related adverse ... See more keywords
Dermatologic Reactions to Immune Checkpoint Inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Clinical Dermatology"
DOI: 10.1007/s40257-017-0336-3
Abstract: The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1)] represents a major breakthrough in cancer therapy. Although they… read more here.
Keywords: immune checkpoint; dermatologic reactions; checkpoint inhibitors; iraes ... See more keywords
Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2018.11.004
Abstract: PURPOSE Nivolumab, an anti-programmed death 1 antibody, produces antitumor effects by activating host immunity, which also causes immune-related adverse events (irAEs). The aim of this study was to analyze the association between antitumor effect and… read more here.
Keywords: nivolumab treatment; group; study; iraes ... See more keywords
Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of cancer"
DOI: 10.1016/j.ejca.2020.03.017
Abstract: BACKGROUND The impact of immune-related adverse events (irAE) on survival outcomes after single-agent immune checkpoint inhibitors (ICIs) remains unclear. We aimed to evaluate the association between irAEs and ICI efficacy in various malignancies. METHODS All… read more here.
Keywords: patients treated; immune related; related adverse; iraes ... See more keywords
Expected and non-expected immune-related adverse events detectable by CT.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of radiology"
DOI: 10.1016/j.ejrad.2021.109617
Abstract: PURPOSE Cancer treatments with immune checkpoint inhibitors (ICI) are associated with a unique set of drug toxicities called immune-related adverse events (irAES). The aim of the present study was to describe the radiological manifestation of… read more here.
Keywords: expected non; immune related; non expected; related adverse ... See more keywords
Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2029414
Abstract: ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have revolutionized treatment for patients with non-small lung cancer (NSCLC). Currently approved ICIs are monoclonal antibodies that target programmed death receptor 1 (PD-1), its ligand PD-L1, or CTLA-4. With… read more here.
Keywords: management; immune related; squamous cell; iraes ... See more keywords
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djad061
Abstract: BACKGROUND Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown. METHODS Characteristics of 812 consecutive solid cancer patients who received… read more here.
Keywords: checkpoint inhibitors; immune checkpoint; interval dosing; dosing immune ... See more keywords
Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Microbiology and immunology"
DOI: 10.1111/1348-0421.13067
Abstract: Immune checkpoint inhibitors (ICIs) have recently improved the prognosis of various cancers. In contrast, some immune-related adverse events (irAEs) caused by ICIs are fatal and have become problematic. The pathogenesis of irAEs remains unknown and… read more here.
Keywords: immune related; iraes; related adverse; occurrence ... See more keywords
Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4– and PD-1–targeted immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abm5663
Abstract: Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab, not only elicit antitumor responses in a wide range of human cancers but also cause severe immune-related adverse events (irAEs), including death. A largely unmet medical… read more here.
Keywords: anti ctla; ctla; immunotherapy; efficacy ... See more keywords